The cytokine stem cell factor (SCF) synergizes with interleukin-7 (IL-7) to enhance the proliferation of pre-B cells. To examine the role of SCF and its receptor, c-kit, in the pathogenesis of pediatric Burkitt's lymphomas (BL), we investigated the expression of SCF and c-kit in BL cells and the mitogenic activity of SCF on BL cells. A panel of 13 BL cell lines and 7 fresh biopsy tumors was investigated. BL cells were stimulated either by Epstein-Barr virus (EBV) infection or by different reagents and cytokines, and expression of SCF and c-kit was studied on the mRNA level by Northern blot analysis and reverse-transcriptase polymerase chain reaction (RT-PCR), followed by Southern blotting. c-kit expression was also studied by fluorescence-activated cell sorting and by crosslinking of digoxigenin-labeled recombinant human SCF to the cell surface. Proliferation of BL cell lines was
lines and 7 fresh biopsy tumors was investigated. BL cells were stimulated either by Epstein-Barr virus (EBV) infection or by different reagents and cytokines, and expression of SCF and c-kit was studied on the mRNA level by Northern blot analysis and reverse-transcriptase polymerase chain reaction (RT-PCR), followed by Southern blotting. c-kit expression was also studied by fluorescence-activated cell sorting and by crosslinking of digoxigenin-labeled recombinant human SCF to the cell surface. Proliferation of BL cell lines was T HE PEDIATRIC non-Hodgkin's lymphomas (NHL) are a heterogenous group of malignancies of B-or T-cell origin that constitute 7% to 10% of all pediatric malignancies. ' In Europe and in North America, approximately 20% to 25% of childhood lymphomas are lymphoblastic lymphomas, half are small noncleaved cell lymphomas (mostly Burkitt's lymphoma [BL] ), and the rest are predominantly large-cell lymphomas.' With current chemotherapy protocols, between 65% and 90% of all patients with BL can achieve long-term disease-free ~urvival.~
The growth conditions of B-cell lymphomas and their dependence on growth factors are of interest, because cytokines are being added to chemotherapy protocols in patients with these conditions. The cytokines interleukin-2 (IL-2), interferon-@ (IFN-p): granulocyte-macrophage colonystimulating factor (GM-CSF),' and granulocyte colony-stimulating factor (G-CSF)6-s have been administered to patients with malignant lymphomas in an effort to modulate the therapeutic response or to alleviate the cytopenias of chemotherapy. The direct in vivo effects on BL cells of the therapeutically used cytokines have not been studied extensively. BL cells could be shown to express IL-2 receptors'"' and could be activated to produce I F N -Y .~ G-CSF receptor were absent on BL cells, which could not be induced to express G-CSF receptors by different reagents. G-CSF did not influence proliferation.'' Lymphomas of different histologies show varying degrees of expression of IL-1, IL-2, IL-4, IL-5, IL-6, GM-CSF, and their receptors. The significance of this finding in the context of a complex cytokine network is often difficult to deter~nine.'~.'~ The recently described hematopoietic cytokine stem cell factor (SCF), also called kit ligand (KL) , mast cell growth factor (MGF), or steel factor (SF), has entered clinical testing as an adjunct in the therapy of malignant d i~e a s e . '~"~ SCF is a pluripotent hematopoietic colony-stimulating factor that binds to its specific surface receptor, a protein encoded by the c-kit proto-oncogene.20-'2 SCF acts synergistically with other growth factors, including erythropoietin (EPO), G-CSF, macrophage colony-stimulating factor (M-CSF), GM-CSF, IL-3, IL-6, IL-11, and IL-12'3-'6 and plays an important Blood, Vol 8 6 , No 4 (August 15). 1995: pp 1469-1480 measured by 3H-thymidine incorporation. Low-level expression of c-kit mRNA was detected in 2 of 13 unstimulated BL cell lines and in 1 fresh BL tumor. One cell line showed upregulation of c-kit mRNA with A23187 and downregulation with phorbol myristate acetate. Neither c-kit nor SCF could be detected in any other cell line under any condition of stimulation as analyzed by Northern blot analysis, RT-PCR followed by Southern blot analysis, crosslinking, and immunofluorescence. No response to SCF was seen in 'Hthymidine incorporation assays. We conclude that most BL cells express neither SCF nor c-kit and that the low-level expression of c-kit in some BL cells most likely has no biologic significance. 0 1995 by The American Society of Hematology.
role in normal and leukemic hematopoiesis. Little is known about the growth factor requirements of BL cells in particular, although normal B cells of different stages of differentiation are known to respond to or require for their growth and differentiation the cytokines IL-1, IL-2, IL-4, IL-6, IL-7, or IL-12.'4,'7 Because of its stimulatory effects on early stem cells, SCF may become a candidate to support not only granulopoiesis but also thrombopoiesis in the setting of highdose chemotherapy. In addition, CSFs are widely used in bone marrow transplantation6*" and SCF appears to be a potent mobilizer of peripheral blood progenitor cells (PBSCS),'~-~' especially in conjunction with G-CSF.6.'5.33 Nothing is known so far about a direct stimulatory or inhibitory effect of SCF on BL cells.
In combination with IL-7, SCF was found to be a potent stimulus at early stages of lymphoid devel~pment.'~.~"~~ Proliferation of murine bone marrow B-lineage cells is supported by stroma cells and IL-7; the stroma cells can be replaced by SCF for the proliferative effect but not for the further differentiation to Ig-expressing cells.34 SCF in combination with IL-6, IL-11, or G-CSF is able to maintain the Blymphoid differentiation potential of primary bone marrow culture^.'^ The combination of SCF and IL-7 provides a proliferative stimulus to murine B cells only after they have differentiated to B220+ cells.34 Murine pro-B-cell and pre-B-cell clones express c-kit, the tyrosine kinase receptor of SCF.35. 39 The finding that c-kit is involved in the growth regulation of pre-B cells makes this receptor a candidate for oncogenic involvement in the development of B-celllineage lymphomas.
For that reason and for the beginning of clinical use of SCF, we examined the direct effect of recombinant human SCF (rhSCF) on pediatric BL cells to elucidate whether SCF is a cytokine that is involved in the growth regulation of these malignancies. We also examined the production of SCF, the presence of the receptor for SCF on BL cells, and the inducibility of SCF and c-kit under different conditions of stimulation.
MATERIALS AND METHODS

Fresh lymphoma cells.
The fresh lymphoma cells were isolated for flow cytometry by Ficoll-Paque centrifugation (Pharmacia, Uppsala, Sweden), washed, and stored in BL medium (see below) containing 10% dimethylsulfoxide (DMSO) and 20% fetal calf serum (FCS) in liquid nitrogen until use. After thawing, the viable cells were again isolated by Ficoll-Paque centrifugation, washed, and resuspended in phosphate-buffered saline (PBS). The percentage of L3 morphology blast cells was determined in each final cell preparation by Wright Giemsa staining. The age and sex of the patient as well as the source and percentage of blast cells in the cell preparation are summarized in Table 1 .
Fresh peripheral blood B and T cells were isolated by FicollPaque centrifugation and subsequent separation over a nylon wool Table 2 . To detect mycoplasma contamination, all cell lines were screened with the Gen-Probe test kit (Biermann, Bad Nauheim, Germany).
The megakaryoblastic cell line M07e46 was used as a positive control for c-kit, whereas the endothelial cell line ECV 30447.48 was used as a positive and the monocytic cell line U93746 as a negative control for SCF mRNA transcripts.
'H-thymidine incorporation assays. The mitogenic activity of rhSCF was determined under serum-free conditions in a 3H-thymidine incorporation assay. BL cell lines were washed three times with serum-free medium consisting of BL medium without FCS, supplemented with Iscove's Supplement (GIBCO BRL) and insulintransferrin-sodium selenite supplement (Boehringer Mannheim, Mannheim, Germany) to a final concentration of 20 pg/mL soy bean lip id^,"^ 1 mg1mL bovine serum albumin (BSA) fraction V, 21 pgl mL transferrin, 1 pg/mL insulin, and 1 ng/mL sodmm selenite. The cells were then plated at a concentration of 5 X IO4 cells/mL in 96-well flat-bottom microtiter plates in 200 pL serum-free BL medium containing various concentrations (0.50, and 500 ng/mL) of rhSCF. After a culture period of 68 hours at 37°C 5% CO2, the cells were exposed to a 4-hour pulse of 0.5 pCi "-thymidine (25 Cilmmol; Amersham, Braunschweig. Germany). Finally, the cells were harvested on glass fiber strips with an automated cell harvester and the incorporated radioactivity was determined by scintillation counting. Northern blot analwis. Total cellular RNA from BL cell lines and fresh BL cells was extracted using the single-step acid guanidinium thiocyanate-phenol-chloroform extraction described by Chomczynski and Sacchi."' Fifteen micrograms of RNA per lane was separated by electrophoresis in a I% agarose gel containing 17% formaldehyde and transferred to a nylon membrane (Hybond N; Amersham) using 3 mol/L NaCI, 0.3 mol/L sodium citrate, pH 7.0 (20X SSC) as transfer buffer. After transfer, the nucleic acids were immobilized by 1,200 pJ of UV irradiation (Stratalinker; Stratagene, La Jolla, CA). Prehybridization was performed for 4 hours and hybridization for 16 hours in IOX SSC containing 50% deionized formamide (Fluka, Buchs, Switzerland), 2.5 mmol/L phosphate buffer (pH 6.5). 5X Denhardt's solution, 75 pg/mL denaturated herring sperm DNA (Serva, Heidelberg, Germany), and 0. I % sodium Fig 1. RT-PCR of SCF transcripts. Using the exon 6-encompassing primer pair, exon &con-taining transcripts generated a 757-bp product, whereas exon 6-negative transcripts generated a 670-bp fragment. Amplified transcripts were separated on a 1.8% agarose gel and stained with ethidium bromide (middle panel). After Southern transfer, the membrane was probed with a Dig-labeled SCF antisense RNA (upper panel at -80°C using intensifying screens. The gels were stained with ethidium bromide to ensure that equal amounts of RNA were loaded.
Preparation of radiolabeled crnrisense RNA probes. The SCF cDNA probe was a 5 19-bp Sma I-Sph I cDNA fragment cloned into the pGEM3-Vector, kindly provided by Dr K.M.
Zsebo (Amgen, Thousand Oaks. CA). The vector was digested with Sac I, and "P-CTP (Amersham) labeled antisense RNA was synthesized using SP6-RNA-polymerase (Boehringer Mannheim). The c-kit probe was a 1.3-kh Sst I fragment derived from phckit-171 (ATCC clone, catalogue no. 59492; deposited by Axel UIIrich"). It was subcloned into the Sac I site of pBluescript KS+ phagemid (pBS KS+; Stratagene). T3-RNA-polymerase (Promega, Heidelberg, Germany) was used to generate "P-CTP-labeled antisense RNA transcripts from the Ava 11-digested vector.
Pol~merasechainreaction(PCR)aFerre,.ersetranscription. Single-stranded cDNA was synthesized from total cellular RNA in 40 ,uL reaction buffer containing I pg random hexamers and 20 U of Moloney murine leukemia virus reverse transcriptase (RT; BRL, Eggenstein, Inactivation of RT reaction was performed at 95°C for 5 minutes. A total of 2.5 pL of this reaction was diluted into 25 pL of PCR buffer containing 7.5 pmol of the upstream and downstream primers. The final MgClz concentration was 1.5 mmol/L.
The set of SCF primers was designed to include exon 6 and therefore to discriminate between the mRNAs for soluble and membrane-bound forms of SCF." Control PCR reactions were performed with specific primers either for aldolase" or 16s mitochondrial ribosomal RNA (16s RNA). The nucleotide sequences of the PCR prim- Table 3 . PCR reactions were started by the addition of 1 U Taq polymerase (Perkin Elmer Cetus, Uberlingen, Germany) in a DNA thermal cycler (Landgraf, Hannover, Germany).
Southern blot ana\ysis. Products from the RT-PCR were separated by electrophoresis in a 1.8% agarose gel in TBE-huffer. DNA was denaturated twice in a buffer containing 0.5 molL NaOH, 1.5 mol/L NaCl and subsequently neutralized twice in a buffer containing 0.5 molL Tris-HCI, 3 molL NaCI, pH 7.5. The gel was checked for the pH and blotted overnight onto a positively charged nylon membrane (Boehringer Mannheim) using 20X SSC as the transfer buffer. After transfer, the DNA was immobilized using an UV crosslinker (Stratalinker; Stratagene) as described in the Northem blot protocol. The membranes were washed briefly in HzO and air dried. Prehybridization and hybridization were performed using a nonradioactive labeling and detection system (Boehringer Mannheim). Digoxigenin (Dig)-labeled SCF antisense RNA probe was generated by using the same vector as for the Northern blot hybridizations. To minimize nonspecific background hybridizations, the vector was additionally digested with Nhe 1 and Sac I and the promotor-containing fragment was isolated from a 1.3% low melting agarose gel (Seaplaque; FMC Bioproducts, Rockland, ME) in TAE buffer. Labeling of the antisense RNA was performed using a Dig-RNA labeling kit (Boehringer Mannheim) according to the manufacturer's instructions. Prehybridization was performed at 50°C in a buffer containing 50% formamide, 5X SSC, 2% blocking reagent (Boehringer Mannheim), 0.1 % sarkosyl, and 0.02% SDS for 3 hours. For hybridization, freshly denaturated Dig-RNA probe was diluted in prehybridization buffer and hybridized overnight at 50°C in a shaking water bath. Stringency washes were performed at 65°C with 2X SSC containing 0.1 % SDS for 1 5 minutes and finally with 0.1 X SSC containing 0. I % SDS at 65°C for 1 5 minutes.
c-kit-specific PCR products were detected with a 5"Dig-labeled oligonucleotide with the sequence 5'-TTGTAAACGATGGAG-AAAATGTA-3' that is complementary to nucleotide position 992 to 1014 of the sequence published by Yarden et Prehybridization was performed at 56°C in a buffer containing 6X SSC, 2% blocking reagent (Boehringer Mannheim), 0.1% sarkosyl, and 0.02% SDS for I hour. For hybridization, 7 pmollmL Dig-labeled oligonucleotide was added to the prehybridization buffer and hybridized for 1 hour in a shaking water bath. The membrane was washed four times at room temperature with 2X SSC, 0.1% SDS for 5 minutes and two times with 0.1 X SSC. 0.1% SDS at 56°C for 2 minutes.
Chemiluminescent detection was performed according to the manufacturer's instructions (Boehringer Mannheim). Briefly, the membranes were washed for 5 minutes in buffer I (0.5 molL maleic acid, 0.15 molL NaCI, pH 7.5). blocked with 1% blocking reagent (Boehringer Mannheim) diluted in buffer 1 (buffer 2) for 30 minutes, and incubated for another 30 was found to have retained mitogenicity for M07e cells comparable to unlabeled rhSCF of the same concentration. M07e and BL cells (5 X IO6 in 1 0 0 pL) were incubated with 15 pL (0.13 mglmL) DigrhSCF for 1 hour on ice in the presence or absence of a 100-fold excess of unlabeled rhSCF. Cells were washed two times with icecold PBS to remove unbound SCF. Subsequently the cells were treated with 0.5 mmol/L of the bifunctional crosslinker disuccinimidylsuberate (DSS; Pierce, Geisenheim. Germany). The reaction was stopped after 45 minutes with 1 0 0 p L of 2 molL glycine, pH 6.8, and the cells were lysed with ice-cold PBS with 1% Triton X-100 (Serva). The soluble proteins were denaturated for 15 minutes at 50°C in a buffer containing 0.06 mol/L Tris, 3% SDS wt/vol, 30% glycerol, l mmol/L phenylmethylsulfonyl fluoride (PMSF), and 15% P-mercaptoethanol and separated in a 7.5% SDS-polyacrylamide gel. The gel was blotted for 1.5 hours in a Sartoblot 11-S sytem at 200 mA onto a Sartolon nylon membrane (Sartorius, Gottingen, Germany) using Bjerrum and Schafer-Nielson's buffer5' containing 48 mmol/L Tris, 39 mmol/L glycine, 20% methanol, 0.0375% SDS, pH 9.5, as the transfer buffer. The membranes were washed twice in 20 mmol/L Tris containing 0.1 % Tween 20, 0.5 mol/L NaCI, pH 7.5, and incubated overnight in blocking buffer containing 100 mL Hank's solution (8 g& NaCI, 0.4 g/L KCI, 0.121 g/L Na2HP0, X 2 H20, 0.1 g/L MgS04 X 7 H20. I g/L glucose X I HzO. 0. I g/L MgC12 X 6 H20, 0.35 g/L NaHC03, 0.3 g/L CaC12 X 6 HzO, 0.01 g/L phenol red), 0.1% Tween 20, and 0.2 g I-Block (Tropix), pH 7.5. The membranes were equilibrated two times with a buffer containing 20 mmoln Tris and 0.05% Tween 20, pH 7.5. Subsequently, the anti-Dig-AP antibody (Boehringer Mannheim) was diluted 1:10,OOO in blocking buffer and the membranes were incubated for 1 hour; washed 7 to 10 times for 5 minutes in 20 mmol/L Tris containing 0. I % Tween 20, 3% dry milk; and equilibrated two times with assay buffer ( I % vol/vol diethanolamin, 1 mmol/L MgCI2, pH 10.0). CSPD stock solution ( I 1.6 mglmL; Tropix) was diluted 1:100 in assay buffer. Membranes were incubated for 30 minutes with 1 mL of diluted CSPD solution at 37°C in a plastic bag. Excess buffer was removed completely and membranes were exposed to Cronex DDS 100 autoradiography films (Du Pont).
N O W c.vfornefn~. Cell samples were incubated for 20 minutes on ice with saturating amounts of monoclonal antibody (MoAb) in I X PBS, 0.5% BSA, 0.1% sodium azide and were washed twice in I X PBS, 0.1 % BSA, 0.1% sodium azide. The MoAbs were stained by fluorescein isothiocyanate (F1TC)-conjugated F(ab')2 rabbit antimouse IgG (Dako, Hamburg, Germany) used as a second-step reagent. All samples were analyzed on a FACScan flow cytometer (Becton Dickinson, San Jose, CA). Primary MoAbs used were anti-CD10 (Calla; Becton Dickinson). anti-CD1 17 (c-kif: supernatant from clone 57ASD8B1 kindly provided by Dr H.-J. Buhring, Tubingen, Germany) and FITC-conjugated rabbit antihuman IgG, IgA, and IgM heavy and light chains (Behring, Marburg, Germany).
RESULTS
RT-PCR of either aldolase mRNA or 16s RNA, The quality of the generated cDNA was judged by amplification of the cDNA with aldolase specific primers that generate a 443-bp product or with 16s RNA specific primers that generate a 752-bp product. RT-PCR and Southern blot analysis of SCF mRNA. SCF exists in both cell surface bound and soluble forms. SCF that is missing 28 amino acids in the extracellular domain is not protease cleavable and therefore remains bound to the cell surface. The 84 DNA basepairs that encode the 28 amino acids correspond precisely to the sixth exon of the human gene.s6-sR The primer pair used in the present experiments discriminates between exon 6-positive and exon 6-negative transcripts. With exon 6-positive transcripts, it generates a 757-bp product. With exon 6-negative transcripts, it generates a 670-bp product. The amplification products were resolved in a 1.8% agarose gel, and the specifity of the products was determined by Southern blot analysis. Only the positive control cell line ECV 304 showed specific SCF transcripts. In all other cell lines, SCF transcripts remained undetectable using RT-PCR after 35 rounds of amplification followed by ethidium bromide staining, as well as using Southern blot analysis (Fig l ) . MHH-BL-2 and BL-16 cells showed nonspecific low molecular weight PCR products for SCF using Southern blot analysis that were not seen on ethidium bromide-stained gels (data not shown).
RT-PCR and Southem blot analysis of c-kit mRNA. Expression of c-kit receptor mRNA was investigated using RT-PCR followed by Southern blot analysis. The positive control cell line M07e showed detectable amounts of c-kit mRNA by RT-PCR on an ethidium bromide-stained agarose gel, whereas MHH-BL-l and BL-18 cells showed low-level expression of c-kit mRNA only detectable by subsequent Southern blot analysis (Fig 2) . These two cell lines were always positive. On repeat PCR examination, the fresh MHH-BL-I cells and the cell lines BL-2 P3HR-I, BL-16, BL-18, BL-41, BL-41 B95-8, and BL-41 P3HR-I were only in some experiments weakly positive. indicating a very low level of expression (data not shown). c-kit mRNA was never detectable in the negative control cell line HL-602" (data not shown). No c-kit mRNA was detected in freshly isolated T and B cells and all other BL cell lines tested (Fig 2) . The question of whether c-kit mRNA was inducible and not expressed constitutively was answered by the addition of PMA or A23187 to the BL cell cultures. Only the cell line MHH-BL-l that already expressed c-kit mRNA showed a gradual upregulation of c-kif mRNA over the time of 48 hours in the presence of A23187 (Fig 3) . whereas the addition of PMA led to a rapid downregulation after 1 hour (Fig 4) . Northern blot analysis of SCF and c-kit mRNA. Northern blot analysis of SCF mRNA expression showed the presence of 5.6-kb and 3.6-kb specific transcripts in the endothelial cell line ECV 304 and a 5.0-kb c-kit specific transcript in the megakaryoblastic cell line M07e used as positive controls. SCF and c-kit mRNA were not detected in the BL cell lines tested. To investigate the possibility that SCF and c-kit mRNA expression is not constitutive but can be induced to a higher level than that found using Southern blot analysis, we stimulated the cell lines with different reagents. Figures  5 and 6 show that the addition of IL-ID, TNF-a, antihuman IgM antibodies, PMA, A23187, and SAC cells to the cell lines for 5 hours before RNA extraction did not result in the induction of SCF and c-kit mRNA.
Receptor expression on BL cells. The SCF binding was determined by chemical crosslinking of Dig-rhSCF to its receptor. The experiment was performed with the cell line M07e used as a positive control and the cell lines MHH-BL-1 and BL-2 P3HR-I, which showed detectable c-kit mRNA expression using RT-PCR and Southern blot analysis. A cytokine-receptor complex of 165 to 170 kD was found only in M07e cells, corresponding to the expected molecular weight of the c-kit receptor of approximately 150 kD. Specific binding of labeled SCF to its receptor could be shown by the addition of 100-fold molar excess of unlabeled SCF. BL cell lines showed no receptor-ligand complex after chemical crosslinking (Fig 7) . Seven fresh BL cell preparations and the cell line M07e were analyzed by FACS for the presence of c-kit receptors. All BL cells were gated for the CD10 antigen and found to express surface Igs. The CD1 17 antigen, the c-kit receptor, was found only on M07e cells used as a positive control but on none of the BL cells (Fig  8) . To determine whether A23 187 treatment, which upregulates c-kit mRNA expression in MHH-BL-I cells, would lead to the expression of c-kit receptors on the protein level, we treated MHH-BL-1 cells for 48 hours with A23 187 before FACS analysis. CD1 17 protein remained undetectable in these stimulated cells (data not shown).
Mitogenic activity of rhSCF on BL cell lines. We tested rhSCF on 13 BL cell lines and used the megakaryoblastic leukemia cell line M07e as a positive control in 'H-thymidine incorporation assays. A significant dose-dependent proliferative response to rhSCF was only detected in the M07e cell line. None of the BL cell lines tested responded to rhSCF (Fig 9) . spontaneous expression of c-kit on the mRNA level in the majority of the BL cells tested.
The possibility, that c-kit is not expressed spontaneously but requires induction by other cytokines or factors present in vivo was explored by in vitro stimulation experiments. BL cells in vivo are exposed to many other factors and cytokines that theoretically could serve as costimulatory factors for SCF by inducing its receptor, especially because low-level expression of c-kit mRNA was detected in some of the BL cells. In our experiments, the cytokines IL-10 and TNF-CY did not induce the expression of c-kit and SCF mRNA as detected by Northern blot analysis. Both cytokines had been found to be highly expressed in lymph nodes from lymphoma patients." These locally produced cytokines were considered most likely to be biologically relevant, because BL cells were also known to express the receptors for ILl" and TNF-CY?' In endothelial cells,h' we previously used these cytokines to induce the expression and showed regula- To detect c-kit regulation on a low level, we performed RT-PCR followed by Southern blot analysis. Only MHH-BL-I cells showed an upregulation of c-kit mRNA in the presence of A23187 and a downregulation in the presence of PMA. c-kit mRNA could also be upregulated by IL-7 in some IL-7 receptor-positive BL cell lines (unpublished observation).
To further investigate the biologic significance of this mRNA expression, we examined c-kit expression on the protein level using FACS analysis and crosslinking experiments and examined the proliferative effect of SCF on BL cells using 'H-thymidine incorporation. The receptor was undetectable on 7 freshly isolated BL cells using FACS analysis and using crosslinking experiments in two BL cell lines with low-level c-kit expression. rhSCF showed no mitogenic effect on the 13 cell lines tested. To find out whether the absence of a proliferative response to exogenous rhSCF could be explained by the autocrine production of SCF or by binding of endogenous SCF to intracellular c-kit receptors leading to its constitutive activation,M we performed RT-PCR from unstimulated BL cells and Northern blot analysis from unstimulated and stimulated BL cells to detect SCF transcripts. Specific SCF mRNA transcripts were not detectable in stimulated and unstimulated BL cell lines using Northern blot analysis or RT-PCR followed by Southern blotting (data from stimulated cells investigated by RT-PCR and Southern blot analysis not shown). From these results we conclude that the low-level c-kit expression detected on the mRNA level has little biologic significance, because ckit mRNA is neither expressed nor inducible in the majority of BL cells and because no protein expression or changes in proliferation were observed on addition of rhSCF.
Some cytokines involved in normal lymphopoiesis can also be involved in the growth of B-cell malignancies. Whether SCF acts synergistically with IL-6 and IL-7 in malignant lymphopoiesis has not been investigated in detail. The autocrine stimulation by IL-6 has been shown in a small number of B-cell lymphoma^.'^^'^^^^ The distribution of both IL-7 receptor and c-kit receptor has been investigated in acute lymphoblastic leukemia cells." Although IL-7 receptors could be detected on the surface of these malignant cells>(' no c-kit I~R N A~~ or surface c-kit protein was expressed?' Expression of both c-kit and SCF was detected in neoplastic cells from human colon c a r~i n o m a >~~~" leading to the suggestion that the autocrine production of SCF plays a role in the growth of some human solid tumor cell lines.-BL cells appear to be derived from more mature B cells that express Igs on their surface. If they behaved like their normal counterpart^,^"^' they would not be expected to express the c-kit receptor. Normal B cells that had progressed in their differentiation to light-chain rearrangement were found not to express the receptor for SCF and IL-7 anymore.".73 Consistent with these findings in normal cells, we were not able to detect c-kit mRNA in freshly isolated normal There are several observations that suggest that SCF is not mandatory for B-lineage expansion in vivo.75 First, in normal mice treated with a neutralizing antibody against ckit, almost all hematopoietic progenitor cells disappeared from the bone marrow, leading to a failure to produce normal numbers of erythroid and myeloid cells, whereas B-cell lymphopoiesis was not significantly affe~ted.~' Second, adult W locus anemic mice, which have functional mutations at the c-kit locus, maintain normal numbers of pre-B and B cells throughout postnatal life.77 These experiments show that B lymphopoiesis is possible in the absence of functional SCF or c-kit. Nevertheless, SCF can be a costimulatory factor for IL-7 in the proliferation of a subpopulation of early B cells." Another subpopulation of B-lineage cells does not require SCF and proliferates in response to IL-7 alone?
From our data we conclude that the lack of c-kit expression on the protein level in BL cells is consistent with their more mature B-cell phenotype. Also, during the process of malignant transformation, the expression of c-kit as a marker of an immature phenotype was not maintained, as apparently happened in the case of the IL-7 receptor. 74 Pinto et
found that expression of c-kit receptor in human lymphomas is restricted to Hodgkin's disease and anaplastic large-cell lymphomas (ALCL). No c-kit expression was found in lymphoid cells of reactive lymph nodes, normal tonsils, and in tumor cells from 24 cases of nonHodgkin's lymphoma other than ALCL.
From our studies we conclude that c-kit and SCF play no role in the process of malignant transformation and in the growth of the pediatric BL cells investigated. Based on these results, we do not expect a direct negative influence of rhSCF on chemotherapeutic treatment outcome in pediatric BL. We also think that a direct stimulation of childhood BL cells or SCF-induced direct mobilization of BL cells during an autologous peripheral stem cell harvest primed by SCF is unlikely. Secondary cytokine effects induced by the treatment of a patient with SCF, such as activation of endothelial cells and stromal elements, cannot be excluded based on our results. Whether a relevant influence on growth of the lymphoma and on treatment outcome arises from the administration of this cytokine can finally be shown only in clinical treatment studies.
